TY - JOUR
T1 - Haematological consequences of acute uncomplicated falciparum malaria
T2 - a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
AU - WorldWide Antimalarial Resistance
AU - Mansoor, Rashid
AU - Commons, Robert J.
AU - Douglas, Nicholas M.
AU - Abuaku, Benjamin
AU - Achan, Jane
AU - Adam, Ishag
AU - Adjei, George O.
AU - Adjuik, Martin
AU - Alemayehu, Bereket H.
AU - Allan, Richard
AU - Allen, Elizabeth N.
AU - Anvikar, Anupkumar R.
AU - Arinaitwe, Emmanuel
AU - Ashley, Elizabeth A.
AU - Ashurst, Hazel
AU - Asih, Puji B. S.
AU - Bakyaita, Nathan
AU - Barennes, Hubert
AU - Barnes, Karen
AU - Basco, Leonardo
AU - Bassat, Quique
AU - Baudin, Elisabeth
AU - Bell, David J.
AU - Bethell, Delia
AU - Bjorkman, Anders
AU - Boulton, Caroline
AU - Bousema, Teun
AU - Brasseur, Philippe
AU - Bukirwa, Hasifa
AU - Burrow, Rebekah
AU - Carrara, Verena
AU - Cot, Michel
AU - D'Alessandro, Umberto
AU - Das, Debashish
AU - Das, Sabyasachi
AU - Davis, Timothy M. E.
AU - Desai, Meghna
AU - Djimde, Abdoulaye A.
AU - Dondorp, Arjen M.
AU - Dorsey, Grant
AU - Drakeley, Chris J.
AU - Duparc, Stephan
AU - Espie, Emmanuelle
AU - Etard, Jean-Francois
AU - Falade, Catherine
AU - Faucher, Jean Francois
AU - Filler, Scott
AU - Fogg, Carole
AU - Fukuda, Mark
AU - Gaye, Oumar
AU - Genton, Blaise
AU - Rahim, Awab Ghulam
AU - Gilayeneh, Julius
AU - Gonzalez, Raquel
AU - Grais, Rebecca F.
AU - Grandesso, Francesco
AU - Greenwood, Brian
AU - Grivoyannis, Anastasia
AU - Hatz, Christoph
AU - Hodel, Eva Maria
AU - Humphreys, Georgina S.
AU - Hwang, Jimee
AU - Ishengoma, Deus
AU - Juma, Elizabeth
AU - Kachur, S. Patrick
AU - Kager, Piet A.
AU - Kamugisha, Erasmus
AU - Kamya, Moses R.
AU - Karema, Corine
AU - Kayentao, Kassoum
AU - Kazienga, Adama
AU - Kiechel, Jean-Rene
AU - Kofoed, Poul-Erik
AU - Koram, Kwadwo
AU - Kremsner, Peter G.
AU - Lalloo, David G.
AU - Laman, Moses
AU - Lee, Sue J.
AU - Lell, Bertrand
AU - Maiga, Amelia W.
AU - Martensson, Andreas
AU - Mayxay, Mayfong
AU - Mbacham, Wilfred
AU - McGready, Rose
AU - Menan, Herve
AU - Menard, Didier
AU - Mockenhaupt, Frank
AU - Moore, Brioni R.
AU - Muller, Olaf
AU - Nahum, Alain
AU - Ndiaye, Jean-Louis
AU - Newton, Paul N.
AU - Ngasala, Billy E.
AU - Nikiema, Frederic
AU - Nji, Akindeh M.
AU - Noedl, Harald
AU - Nosten, Francois
AU - Ogutu, Bernhards R.
AU - Ojurongbe, Olusola
AU - Osorio, Lyda
AU - Ouedraogo, Jean-Bosco
AU - Owusu-Agyei, Seth
AU - Pareek, Anil
AU - Penali, Louis K.
AU - Piola, Patrice
AU - Plucinski, Mateusz
AU - Premji, Zul
AU - Ramharter, Michael
AU - Richmond, Caitlin L.
AU - Rombo, Lars
AU - Rosenthal, Philip J.
AU - Salman, Sam
AU - Same-Ekobo, Albert
AU - Sibley, Carol
AU - Sirima, Sodiomon B.
AU - Smithuis, Frank M.
AU - Some, Fabrice A.
AU - Staedke, Sarah G.
AU - Starzengruber, Peter
AU - Strub-Wourgaft, Nathalie
AU - Sutanto, Inge
AU - Swarthout, Todd D.
AU - Syafruddin, Din
AU - Talisuna, Ambrose O.
AU - Taylor, Walter R.
AU - Temu, Emmanuel A.
AU - Thwing, Julie
AU - Tinto, Halidou
AU - Tjitra, Emiliana
AU - Toure, Offianan A.
AU - Tran, T. Hien
AU - Ursing, Johan
AU - Valea, Innocent
AU - Valentini, Giovanni
AU - van Vugt, Michele
AU - von Seidlein, Lorenz
AU - Ward, Stephen A.
AU - Were, Vincent
AU - White, Nicholas J.
AU - Woodrow, Charles J.
AU - Yavo, William
AU - Yeka, Adoke
AU - Zongo, Issaka
AU - Simpson, Julie A.
AU - Guerin, Philippe J.
AU - Stepniewska, Kasia
AU - Price, Ric N.
AU - Roper, Cally
PY - 2022/12
Y1 - 2022/12
N2 - Background Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. Methods Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall >= 25% at day 3 and day 7. Results A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0-19.7 g/dL) in Africa, 11.6 g/dL (range 5.0-20.0 g/dL) in Asia and 12.3 g/dL (range 6.9-17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to >= 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39-3.05], p < 0.001). Conclusions In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.
AB - Background Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. Methods Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall >= 25% at day 3 and day 7. Results A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0-19.7 g/dL) in Africa, 11.6 g/dL (range 5.0-20.0 g/dL) in Asia and 12.3 g/dL (range 6.9-17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to >= 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39-3.05], p < 0.001). Conclusions In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.
KW - Plasmodium falciparum
KW - Artemisinin-based therapy
KW - Non-artemisinin-based therapy
KW - Antimalarials
KW - Haemoglobin
KW - Severe anaemia
KW - Pooled analysis of individual patient data
KW - PLUS SULFADOXINE-PYRIMETHAMINE
KW - ARTEMETHER-LUMEFANTRINE COARTEM(R)
KW - RANDOMIZED CONTROLLED-TRIAL
KW - FIXED-DOSE COMBINATIONS
KW - IN-VIVO EFFICACY
KW - PLASMODIUM-FALCIPARUM
KW - DIHYDROARTEMISININ-PIPERAQUINE
KW - ARTESUNATE-MEFLOQUINE
KW - OPEN-LABEL
KW - DOUBLE-BLIND
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000765127700001
U2 - 10.1186/s12916-022-02265-9
DO - 10.1186/s12916-022-02265-9
M3 - Article
C2 - 35249546
SN - 1741-7015
VL - 20
JO - BMC Medicine
JF - BMC Medicine
IS - 1
M1 - 85
ER -